Extended Phase 2 study reveals efficacy of macrophage cell therapy
Resolution Therapeutics Limited, in collaboration with the University of Edinburgh, presented compelling clinical data at the EASL Congress 2024 in Milan, Italy, demonstrating the great potential of macrophage cell therapy in the treatment of advanced liver cirrhosis.
The MATCH Phase 2 trial, led by Dr Paul Brennan and Professor Stuart Forbes at the University of Dundee, found that non-genetically modified autologous macrophages were safe and effective for patients with cirrhosis, with significant improvements in patient survival and transplant-free survival over 30 months after randomization.
Professor Forbes, Founder of Resolution Therapeutics and Professor of Transplantation and Regenerative Medicine at the University of Edinburgh, reflected: “We are extremely encouraged by the data from the MATCH Phase 2 trial and this long-term follow-up. We will continue to monitor patients with the aim of reporting further data at the AASLD meeting in November 2024.”
Resolution has also introduced a proprietary discovery platform for engineered macrophage cell therapy, spearheaded by Dr. Lara Campana.
The platform enhances differentiation protocols and automates processes to maximize manufacturing yields.
This innovation allows for multiple doses to be administered from a single leukapheresis collection, significantly improving the efficiency and robustness of the manufacturing process.
The MATCH 2 data provide clear clinical proof of concept for macrophage cell therapy as a durable treatment for advanced cirrhosis.
Resolution currently holds exclusive rights to the technology and data under licence from the University of Edinburgh and Edinburgh Innovations.
Resolution’s upcoming Phase 1/2 EMERALD trial will further explore the safety and efficacy of RTX001, an engineered macrophage cell therapy, in patients with decompensated cirrhosis and represent a major step forward towards solving this challenging condition.
